Lee, R S C
Hermens, D F
Naismith, S L
Lagopoulos, J
Jones, A
Scott, J
Chitty, K M
White, D
Robillard, R
Scott, E M
Hickie, I B
Article History
Received: 9 December 2014
Revised: 2 March 2015
Accepted: 9 March 2015
First Online: 28 April 2015
Competing interests
: IBH has led projects for health professionals and the community supported by governmental, community agency and drug industry partners (Wyeth, Eli Lily, Servier, Pfizer and AstraZeneca) for the identification and management of depression and anxiety. He has served on advisory boards convened by the drug industry in relation to specific antidepressants, including nefazodone, duloxetine and desvenlafaxine, and has participated in a multicenter clinical trial of agomelatine effects on sleep architecture in depression. He has participated in Servier-sponsored educational programs related to circadian-based therapies. DFH has previously received honoraria for educational seminars from Janssen-Cilag. The research by JS has been supported by funds provided to the Northumberland, Tyne and Wear National Health Service Trust by AstraZeneca and Janssen-Cilag for investigator-initiated studies on medication adherence. She has received honoraria for educational seminars supported by the pharmaceutical industry and has served on advisory boards convened by the pharmaceutical industry (including AstraZeneca, Janssen-Cilag, Lundbeck, Pfizer, Sanofi-Aventis and Servier). EMS has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli-Lilly pharmaceuticals. She has also participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. The remaining authors declare no conflict of interest.